{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:25:00Z","timestamp":1794223500337,"version":"4.8.0"},"reference-count":185,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Allergen immunotherapy (AIT) remains the only disease-modifying treatment for immunoglobulin (Ig) E-mediated allergic diseases, including allergic rhinitis (AR), asthma, food allergy, and atopic dermatitis (AD). This review provides a comprehensive update on recent advances in AIT, focusing on immunological mechanisms, novel vaccines, biomarkers, clinical outcomes across different diseases, and emerging combination strategies with biologics. We discussed the pivotal roles of regulatory T and B cells, innate lymphoid cells (ILCs), and blocking antibodies (immunoglobulin G4 [IgG4], immunoglobulin A [IgA]) in establishing long-term tolerance. Novel allergen vaccines\u2014including recombinant and hypoallergenic derivatives, virus-like particle (VLP) conjugates, and transgenic peptide vaccines\u2014aim to improve safety and efficacy. We critically evaluate current biomarkers for predicting and monitoring AIT response, such as the allergen-specific IgE (sIgE)\/total immunoglobulin E (tIgE) ratio, basophil activation test, and cellular markers. Clinical evidence supports AIT efficacy in asthma, AR, and AD, with emerging applications in food allergies. Furthermore, combining AIT with biologics (e.g., anti-IgE and anti-interleukin [IL]-4\/IL-4 receptor [IL-4R]) shows promise in enhancing safety and efficacy, particularly in severe asthma. Despite these advances, challenges remain in patient selection, treatment duration, and extract standardization. Future research should prioritize predictive biomarkers, short-course regimens, and synergistic biologic-AIT approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004189","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:00:08Z","timestamp":1784862008000},"page":"2552-2569","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in allergen immunotherapy"],"prefix":"10.1097","volume":"139","author":[{"given":"Wei","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, Hubei,430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Allergy, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang,310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei,430033, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, Hubei,430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, Hubei,430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, Hubei,430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Allergy, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang,310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezmi A","family":"Akdis","sequence":"additional","affiliation":[{"name":"Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos,\u00a0 7270, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, Hubei,430071, China"},{"name":"Department of Allergy, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang,310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"R1-20261109","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pccm.2024.08.004","article-title":"Patterns and trends in asthma incidence rates in main Asian and Western countries and their prediction to 2030","volume":"2","author":"Zheng","year":"2024","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"R2-20261109","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/all.16103","article-title":"EAACI guidelines on environmental science for allergy and asthma: The impact of short-term exposure to outdoor air pollutants on asthma-related outcomes and recommendations for mitigation measures","volume":"79","author":"Agache","year":"2024","journal-title":"Allergy"},{"key":"R3-20261109","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/CM9.0000000000001983","article-title":"Involvement and therapeutic implications of airway epithelial barrier dysfunction in type 2 inflammation of asthma","volume":"135","author":"Dong","year":"2022","journal-title":"Chin Med J"},{"key":"R4-20261109","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/all.15945","article-title":"Hot topics in allergen immunotherapy, 2023: Current status and future perspective","volume":"79","author":"Zemelka-Wiacek","year":"2024","journal-title":"Allergy"},{"key":"R5-20261109","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/all.15023","article-title":"One hundred and ten years of allergen immunotherapy: A journey from empiric observation to evidence","volume":"77","author":"Pfaar","year":"2022","journal-title":"Allergy"},{"key":"R6-20261109","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41577-022-00786-1","article-title":"Allergen immunotherapy: Past, present and future","volume":"23","author":"Durham","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"R7-20261109","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/ACI.0000000000000707","article-title":"Allergen immunotherapy and biologics in respiratory allergy: Friends or foes?","volume":"21","author":"Malipiero","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R8-20261109","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1067\/mai.2001.112263","article-title":"TH2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens","volume":"107","author":"Guerra","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"R9-20261109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/ped.2014.0328","article-title":"Sublingual immunotherapy for asthma: Affects T-cells but does not impact basophil activation","volume":"27","author":"Ciepiela","year":"2014","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"R10-20261109","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000503143","article-title":"Changes in CD4+CD25+FoxP3+ regulatory T cells and serum cytokines in sublingual and subcutaneous immunotherapy in allergic rhinitis with or without asthma","volume":"181","author":"Xian","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"R11-20261109","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100715","article-title":"Specific immunoglobulin G4 correlates with Th2 cytokine reduction in patients with allergic asthma treated by Dermatophagoides pteronyssinus subcutaneous immunotherapy","volume":"16","author":"Su","year":"2023","journal-title":"World Allergy Organ J"},{"key":"R12-20261109","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1034\/j.1399-3038.2003.00054.x","article-title":"Both allergen-specific CD4 and CD8 type 2 T cells decreased in asthmatic children with immunotherapy","volume":"14","author":"Fu","year":"2003","journal-title":"Pediatr Allergy Immunol"},{"key":"R13-20261109","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cea.14432","article-title":"Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy","volume":"54","author":"Starchenka","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"R14-20261109","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/all.13684","article-title":"Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy","volume":"74","author":"Boonpiyathad","year":"2019","journal-title":"Allergy"},{"key":"R15-20261109","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2222.2004.01823.x","article-title":"Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy","volume":"34","author":"Savolainen","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"R16-20261109","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cyto.2012.10.005","article-title":"Bee venom ameliorates ovalbumin induced allergic asthma via modulating CD4+CD25+ regulatory T cells in mice","volume":"61","author":"Choi","year":"2013","journal-title":"Cytokine"},{"key":"R17-20261109","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1164\/rccm.200905-0686OC","article-title":"House dust mite sublingual immunotherapy: The role for transforming growth factor-beta and functional regulatory T cells","volume":"180","author":"O\u2019Hehir","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20261109","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jaci.2018.06.041","article-title":"Role of IL-35 in sublingual allergen immunotherapy","volume":"143","author":"Shamji","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R19-20261109","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/all.14639","article-title":"Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy","volume":"76","author":"Yao","year":"2021","journal-title":"Allergy"},{"key":"R20-20261109","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm.2425","article-title":"Foxp3+ follicular regulatory T cells control the germinal center response","volume":"17","author":"Linterman","year":"2011","journal-title":"Nat Med"},{"key":"R21-20261109","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaci.2019.02.023","article-title":"Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial","volume":"144","author":"Sharif","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R22-20261109","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2019.02.008","article-title":"Allergen immunotherapy improves defective follicular regulatory T cells in patients with allergic rhinitis","volume":"144","author":"Yao","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20261109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/imr.12937","article-title":"B regulatory cells in allergy","volume":"299","author":"Ma","year":"2021","journal-title":"Immunol Rev"},{"key":"R24-20261109","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/cea.12238","article-title":"CD24(hi)CD27(+) B cells from patients with allergic asthma have impaired regulatory activity in response to lipopolysaccharide","volume":"44","author":"van der Vlugt","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"R25-20261109","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jaci.2013.01.014","article-title":"IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses","volume":"131","author":"van de Veen","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R26-20261109","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaci.2018.10.061","article-title":"Role of Der p 1-specific B cells in immune tolerance during 2\u00a0years of house dust mite-specific immunotherapy","volume":"143","author":"Boonpiyathad","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R27-20261109","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ACI.0000000000000400","article-title":"The role of regulatory B cells in allergen immunotherapy","volume":"17","author":"van de Veen","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R28-20261109","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2016.07.006","article-title":"Role of regulatory B cells in immune tolerance to allergens and beyond","volume":"138","author":"van de Veen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 25","key":"R29-20261109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/pai.13189","article-title":"EAACI allergen immunotherapy user\u2019s guide","volume":"31","author":"Alvaro-Lozano","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"R30-20261109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaci.2015.09.015","article-title":"Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy","volume":"137","author":"Gueguen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R31-20261109","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.jaci.2020.08.042","article-title":"Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy","volume":"147","author":"Eljaszewicz","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R32-20261109","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.immuni.2015.06.021","article-title":"An Interleukin-33-mast cell-Interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers","volume":"43","author":"Morita","year":"2015","journal-title":"Immunity"},{"key":"R33-20261109","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jaci.2014.07.029","article-title":"Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy","volume":"134","author":"Lao-Araya","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R34-20261109","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.immuni.2020.12.013","article-title":"Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response","volume":"54","author":"Golebski","year":"2021","journal-title":"Immunity"},{"key":"R35-20261109","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0036-2023","article-title":"Natural killer cells in the lung: Potential role in asthma and virus-induced exacerbation?","volume":"32","author":"Lepretre","year":"2023","journal-title":"Eur Respir Rev"},{"key":"R36-20261109","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1081-1206(10)60936-2","article-title":"Production of interleukin-12 by monocytes and interferon-gamma by natural killer cells in allergic patients during rush immunotherapy","volume":"97","author":"Plewako","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R37-20261109","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/all.13465","article-title":"Allergen-specific immunotherapy induces regulatory T cells in an atopic dermatitis mouse model","volume":"73","author":"Shin","year":"2018","journal-title":"Allergy"},{"key":"R38-20261109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cei.12399","article-title":"Activation of invariant natural killer T cells in regional lymph nodes as new antigen-specific immunotherapy via induction of interleukin-21 and interferon-\u03b3","volume":"178","author":"Sakurai","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"R39-20261109","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/cea.12975","article-title":"Invariant natural killer cells change after an oral allergy desensitization protocol for cow\u2019s milk","volume":"47","author":"Cianferoni","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"R40-20261109","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jaci.2021.06.012","article-title":"Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring","volume":"149","author":"Benito-Villalvilla","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R41-20261109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cea.14261","article-title":"From trained immunity in allergy to trained immunity-based allergen vaccines","volume":"53","author":"Mart\u00edn-Cruz","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"R42-20261109","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1046\/j.1365-2222.1999.00678.x","article-title":"Grass pollen immunotherapy decreases the number of mast cells in the skin","volume":"29","author":"Durham","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"R43-20261109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaci.2005.03.011","article-title":"IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy","volume":"116","author":"Nouri-Aria","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R44-20261109","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.898494","article-title":"Mast cell desensitization in allergen immunotherapy","volume":"3","author":"L\u00f3pez-Sanz","year":"2022","journal-title":"Front Allergy"},{"key":"R45-20261109","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaci.2012.04.039","article-title":"Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2","volume":"130","author":"Novak","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R46-20261109","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1046\/j.1365-2222.2001.01231.x","article-title":"Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium","volume":"31","author":"Wilson","year":"2001","journal-title":"Clin Exp Allergy"},{"issue":"3 Pt 1","key":"R47-20261109","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0091-6749(88)90021-8","article-title":"The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients","volume":"82","author":"Rak","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"R48-20261109","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1038\/s41598-018-26221-x","article-title":"Allergy immunotherapy restores airway epithelial barrier dysfunction through suppressing IL-25-induced endoplasmic reticulum stress in asthma","volume":"8","author":"Yuan","year":"2018","journal-title":"Sci Rep"},{"key":"R49-20261109","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00446-2022","article-title":"Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: A nationwide epidemiological study","volume":"60","author":"Woehlk","year":"2022","journal-title":"Eur Respir J"},{"key":"R50-20261109","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.202209-1708OC","article-title":"Allergen immunotherapy enhances airway epithelial antiviral immunity in patients with allergic asthma (VITAL Study): A double-blind randomized controlled trial","volume":"207","author":"Woehlk","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"R51-20261109","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/cea.13254","article-title":"Birch pollen-specific subcutaneous immunotherapy reduces ILC2 frequency but does not suppress IL-33 in mice","volume":"48","author":"van Rijt","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"R52-20261109","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaci.2023.07.009","article-title":"Advancing precision medicine in asthma: Evolution of treatment outcomes","volume":"152","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R53-20261109","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/all.14908","article-title":"The role of allergen-specific IgE, IgG and IgA in allergic disease","volume":"76","author":"Shamji","year":"2021","journal-title":"Allergy"},{"key":"R54-20261109","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2018.09.039","article-title":"Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy","volume":"143","author":"Shamji","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R55-20261109","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cea.12241","article-title":"Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy","volume":"44","author":"Aasbjerg","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"R56-20261109","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaci.2022.01.016","article-title":"Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma","volume":"149","author":"Shamji","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R57-20261109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/all.16248","article-title":"On the role of antibody affinity and avidity in the IgE-mediated allergic response","volume":"80","author":"Bachmann","year":"2025","journal-title":"Allergy"},{"key":"R58-20261109","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.4049\/jimmunol.178.7.4658","article-title":"Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression","volume":"178","author":"Pilette","year":"2007","journal-title":"J Immunol"},{"key":"R59-20261109","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.70097","article-title":"Subcutaneous allergen-specific immunotherapy for allergic rhinitis: Divergent IgA responses in nasal mucosa and blood with validation of B cell class-switching in lymph nodes and blood","volume":"15","author":"Jafari","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"R60-20261109","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/all.14133","article-title":"Allergen-specific immunotherapy boosts allergen-specific IgD production in house dust mite-sensitized asthmatic patients","volume":"75","author":"Boonpiyathad","year":"2020","journal-title":"Allergy"},{"key":"R61-20261109","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/pai.13001","article-title":"\u201cMolecular extracts\u201d for allergy diagnostics and therapy","volume":"30","author":"Matricardi","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"R62-20261109","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1111\/all.14969","article-title":"Molecular allergology and its impact in specific allergy diagnosis and therapy","volume":"76","author":"Barber","year":"2021","journal-title":"Allergy"},{"key":"R63-20261109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/all.14300","article-title":"Past, present, and future of allergen immunotherapy vaccines","volume":"76","author":"Dorofeeva","year":"2021","journal-title":"Allergy"},{"key":"R64-20261109","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2008.09.017","article-title":"Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis","volume":"122","author":"Pauli","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"R65-20261109","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaci.2019.02.029","article-title":"Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1","volume":"144","author":"Tabar","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R66-20261109","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1365-2222.2012.03971.x","article-title":"Specific subcutaneous immunotherapy with recombinant grass pollen allergens: First randomized dose-ranging safety study","volume":"42","author":"Klimek","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"R67-20261109","article-title":"Immunotherapy with recombinant Alt a 1 suppresses allergic asthma and influences T follicular cells and regulatory B cells in mice","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"R68-20261109","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/j.vaccine.2011.11.011","article-title":"Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives","volume":"30","author":"Linhart","year":"2012","journal-title":"Vaccine"},{"key":"R69-20261109","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2017.04.015","article-title":"Recombinant allergy vaccines based on allergen-derived B cell epitopes","volume":"189","author":"Valenta","year":"2017","journal-title":"Immunol Lett"},{"key":"R70-20261109","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jaci.2015.03.034","article-title":"Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients","volume":"136","author":"Niederberger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R71-20261109","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaci.2017.09.052","article-title":"Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32","volume":"142","author":"Niederberger","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R72-20261109","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ebiom.2019.11.006","article-title":"Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response","volume":"50","author":"Eckl-Dorna","year":"2019","journal-title":"EBioMedicine"},{"key":"R73-20261109","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/all.13996","article-title":"Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells","volume":"75","author":"Rauber","year":"2020","journal-title":"Allergy"},{"key":"R74-20261109","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/all.14096","article-title":"Virus-like particles displaying major house dust mite allergen Der p 2 for prophylactic allergen immunotherapy","volume":"75","author":"Soongrung","year":"2020","journal-title":"Allergy"},{"key":"R75-20261109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00253-020-11012-0","article-title":"Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them","volume":"105","author":"Sani","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"R76-20261109","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/all.13573","article-title":"Prevention of allergy by virus-like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model","volume":"74","author":"Kratzer","year":"2019","journal-title":"Allergy"},{"key":"R77-20261109","doi-asserted-by":"crossref","first-page":"13127","DOI":"10.1021\/acs.jafc.9b05421","article-title":"Development of rice-seed-based oral allergy vaccines containing hypoallergenic Japanese cedar pollen allergen derivatives for immunotherapy","volume":"67","author":"Takaiwa","year":"2019","journal-title":"J Agric Food Chem"},{"key":"R78-20261109","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2500\/aap.2021.42.210011","article-title":"Long-term oral administration of transgenic rice containing cedar pollen T-cell epitopes potentially improves medication- and allergy-related quality-of-life scores","volume":"42","author":"Endo","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"R79-20261109","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3390\/cells10123361","article-title":"Prophylactic and therapeutic effects of oral immunotherapy on birch pollen-induced allergic conjunctivitis in mice with a rice-based edible vaccine expressing a hypoallergenic birch pollen allergen","volume":"10","author":"Ishida","year":"2021","journal-title":"Cells"},{"key":"R80-20261109","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41467-018-03636-8","article-title":"Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement","volume":"9","author":"Orengo","year":"2018","journal-title":"Nat Commun"},{"key":"R81-20261109","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/all.15740","article-title":"Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI task force report","volume":"78","author":"Bousquet","year":"2023","journal-title":"Allergy"},{"key":"R82-20261109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clim.2010.12.022","article-title":"Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis","volume":"139","author":"Fujimura","year":"2011","journal-title":"Clin Immunol"},{"key":"R83-20261109","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1993768","article-title":"Impact of IgG subclass on molecular properties of monoclonal antibodies","volume":"13","author":"Tang","year":"2021","journal-title":"MAbs"},{"key":"R84-20261109","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/all.14073","article-title":"Induction of IgG2 and IgG4 B-cell memory following sublingual immunotherapy for ryegrass pollen allergy","volume":"75","author":"Heeringa","year":"2020","journal-title":"Allergy"},{"key":"R85-20261109","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/all.15107","article-title":"Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy","volume":"77","author":"Bordas-Le Floch","year":"2022","journal-title":"Allergy"},{"key":"R86-20261109","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/0091-6749(90)90043-4","article-title":"A long-term follow-up study of hyposensitization with immunoblotting","volume":"85","author":"Jarolim","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"R87-20261109","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0091-6749(92)90318-V","article-title":"Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy","volume":"89","author":"Peng","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"R88-20261109","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaci.2023.01.005","article-title":"The role of IgG1 and IgG4 as dominant IgE-blocking antibodies shifts during allergen immunotherapy","volume":"151","author":"Strobl","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R89-20261109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000444391","article-title":"The functional IgE-blocking factor induced by allergen-specific immunotherapy correlates with IgG4 antibodies and a decrease of symptoms in house dust mite-allergic children","volume":"169","author":"Zhao","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"R90-20261109","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/all.13138","article-title":"Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: An EAACI Position Paper","volume":"72","author":"Shamji","year":"2017","journal-title":"Allergy"},{"key":"R91-20261109","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jim.2006.09.004","article-title":"The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses","volume":"317","author":"Shamji","year":"2006","journal-title":"J Immunol Methods"},{"key":"R92-20261109","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1398-9995.2011.02745.x","article-title":"Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy","volume":"67","author":"Shamji","year":"2012","journal-title":"Allergy"},{"key":"R93-20261109","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.4049\/jimmunol.1701690","article-title":"Functional and immunoreactive levels of IgG4 correlate with clinical responses during the maintenance phase of house dust mite immunotherapy","volume":"200","author":"Feng","year":"2018","journal-title":"J Immunol"},{"key":"R94-20261109","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cea.14088","article-title":"Suppression function against environmental dust exposure after Dermatophagoides pteronyssinus immunotherapy is associated with production of specific and cross-reactive immunoglobulin G4","volume":"52","author":"Feng","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"R95-20261109","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1111\/all.14747","article-title":"Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice","volume":"76","author":"Santos","year":"2021","journal-title":"Allergy"},{"key":"R96-20261109","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2222.2010.03572.x","article-title":"Expression of CD203c and CD63 in human basophils: Relationship to differential regulation of piecemeal and anaphylactic degranulation processes","volume":"40","author":"MacGlashan","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"R97-20261109","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1111\/j.1365-2222.2009.03379.x","article-title":"Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: Clinical and immunological effects","volume":"39","author":"Ceuppens","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"R98-20261109","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/cea.12578","article-title":"Initial immunological changes as predictors for house dust mite immunotherapy response","volume":"45","author":"G\u00f3mez","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"R99-20261109","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jaci.2017.09.041","article-title":"Synchronous immune alterations mirror clinical response during allergen immunotherapy","volume":"141","author":"Renand","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R100-20261109","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/all.14585","article-title":"Basophil activation test: A diagnostic, predictive and monitoring assay for allergen immunotherapy","volume":"76","author":"Alpan","year":"2021","journal-title":"Allergy"},{"key":"R101-20261109","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jaci.2022.01.011","article-title":"Which patients with asthma are most likely to benefit from allergen immunotherapy?","volume":"149","author":"de Blay","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R102-20261109","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2222.2010.03462.x","article-title":"Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells","volume":"40","author":"Scadding","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"R103-20261109","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/all.12966","article-title":"High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers","volume":"72","author":"Boonpiyathad","year":"2017","journal-title":"Allergy"},{"key":"R104-20261109","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jaci.2012.02.014","article-title":"A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy","volume":"129","author":"Zimmer","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R105-20261109","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaci.2017.04.032","article-title":"Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells","volume":"141","author":"Schulten","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R106-20261109","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/all.12608","article-title":"Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge","volume":"70","author":"Scadding","year":"2015","journal-title":"Allergy"},{"key":"R107-20261109","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/all.16386","article-title":"Enhanced benefit from house dust mite immunotherapy in subjects with low serum levels of LILRA5 or CCL25","volume":"80","author":"Bordas-Le Floch","year":"2025","journal-title":"Allergy"},{"key":"R108-20261109","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/all.12586","article-title":"In vivo diagnosis of allergic diseases--allergen provocation tests","volume":"70","author":"Agache","year":"2015","journal-title":"Allergy"},{"key":"R109-20261109","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/pai.12807","article-title":"EAACI guidelines on allergen immunotherapy: Prevention of allergy","volume":"28","author":"Halken","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"R110-20261109","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13052-016-0315-y","article-title":"Clinical practice recommendations for allergen-specific immunotherapy in children: The Italian consensus report","volume":"43","author":"Pajno","year":"2017","journal-title":"Ital J Pediatr"},{"key":"R111-20261109","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1111\/all.15817","article-title":"Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper","volume":"78","author":"Kappen","year":"2023","journal-title":"Allergy"},{"key":"R112-20261109","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/all.13749","article-title":"EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma","volume":"74","author":"Agache","year":"2019","journal-title":"Allergy"},{"key":"R113-20261109","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pccm.2023.07.002","article-title":"Small airways in asthma: Pathophysiology, identification and management","volume":"1","author":"Toumpanakis","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"R114-20261109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.723814","article-title":"Effectiveness of sublingual immunotherapy in the treatment of HDM-induced nasobronchial allergies: A 3-year randomized case-control study from Kashmir","volume":"12","author":"Baba","year":"2021","journal-title":"Front Immunol"},{"key":"R115-20261109","doi-asserted-by":"crossref","first-page":"362","DOI":"10.18176\/jiaci.0832","article-title":"A 5-Year open-label follow-up of a randomized double-blind placebo-controlled trial of intralymphatic immunotherapy for birch and grass allergy reveals long-term beneficial effects","volume":"33","author":"Hjalmarsson","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R116-20261109","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaip.2019.09.002","article-title":"Efficacy and safety of HDM SLIT tablet in Japanese adults with allergic asthma","volume":"8","author":"Tanaka","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R117-20261109","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/pai.13332","article-title":"Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis","volume":"32","author":"Liu","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"R118-20261109","article-title":"Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis","volume":"3","author":"Hoshino","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"R119-20261109","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02782-2021","article-title":"Allergen provocation tests in respiratory research: Building on 50 years of experience","volume":"60","author":"Gauvreau","year":"2022","journal-title":"Eur Respir J"},{"key":"R120-20261109","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13601-020-00336-9","article-title":"Allergen exposure chambers: Implementation in clinical trials in allergen immunotherapy","volume":"10","author":"Pfaar","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"R121-20261109","article-title":"Innovative delivery systems for epicutaneous immunotherapy","volume":"14","author":"Wang","year":"2023","journal-title":"FrontImmunol"},{"key":"R122-20261109","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.anai.2023.11.030","article-title":"Intralymphatic immunotherapy: A status update","volume":"132","author":"Smith","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R123-20261109","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/ACI.0b013e3283310ff7","article-title":"Intralymphatic immunotherapy","volume":"9","author":"Senti","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R124-20261109","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/imm.13898","article-title":"Efficacy of subcutaneous, sublingual and oral immunotherapy for allergens: A comparative study","volume":"174","author":"Lisiecka","year":"2025","journal-title":"Immunology"},{"key":"R125-20261109","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000493647","article-title":"Intralymphatic immunotherapy: Update and unmet needs","volume":"178","author":"Senti","year":"2018","journal-title":"Int Arch Allergy Immunol"},{"key":"R126-20261109","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jaci.2018.05.030","article-title":"Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial","volume":"142","author":"Hellkvist","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R127-20261109","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jaci.2019.11.017","article-title":"Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: A randomized trial","volume":"145","author":"Konradsen","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R128-20261109","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1709531","article-title":"Efficacy and safety of intralymphatic immunotherapy for allergic rhinitis: An overview of systematic reviews and meta analyses","volume":"12","author":"Wang","year":"2025","journal-title":"Front Med"},{"key":"R129-20261109","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9377518","article-title":"Evaluation of intralymphatic immunotherapy in allergic rhinitis patients: A systematic review and meta-analysis","volume":"2023","author":"Jiang","year":"2023","journal-title":"Mediators Inflamm"},{"key":"R130-20261109","article-title":"Intratonsillar immunotherapy: A convenient and effective alternative to subcutaneous immunotherapy for allergic rhinitis","volume":"8","author":"Gu","year":"2025","journal-title":"Research (Wash D C)"},{"key":"R131-20261109","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.anai.2023.10.029","article-title":"Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial","volume":"132","author":"Zhang","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R132-20261109","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl0406","article-title":"Liver-targeted allergen immunotherapy rapidly and safely induces antigen-specific tolerance to treat allergic airway disease in mice","volume":"17","author":"G\u00f3mez Medell\u00edn","year":"2025","journal-title":"Sci Transl Med"},{"key":"R133-20261109","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2020.12.016","article-title":"A randomized trial of subcutaneous allergy immunotherapy in inner-city children with asthma less than 4\u00a0years of age","volume":"126","author":"de Vos","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R134-20261109","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2020.01.048","article-title":"Primary prevention of asthma in high-risk children using HDM SLIT: Assessment at age 6\u00a0years","volume":"145","author":"Alviani","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R135-20261109","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaci.2017.06.014","article-title":"Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy","volume":"141","author":"Valovirta","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R136-20261109","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"key":"R137-20261109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/all.12791","article-title":"House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: A clinical trial","volume":"71","author":"Devillier","year":"2016","journal-title":"Allergy"},{"key":"R138-20261109","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3892\/etm.2014.1469","article-title":"Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma","volume":"7","author":"Hui","year":"2014","journal-title":"Exp Ther Med"},{"key":"R139-20261109","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.rmed.2014.07.017","article-title":"SQ HDM SLIT-tablet (ALK) in treatment of asthma \u2013 post hoc results from a randomized trial","volume":"108","author":"de Blay","year":"2014","journal-title":"Respir Med"},{"key":"R140-20261109","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jaci.2013.08.047","article-title":"Development of cockroach immunotherapy by the inner-city asthma consortium","volume":"133","author":"Wood","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R141-20261109","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/all.13705","article-title":"Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France","volume":"74","author":"Devillier","year":"2019","journal-title":"Allergy"},{"key":"R142-20261109","article-title":"Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study","volume":"13","author":"Fritzsching","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"R143-20261109","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1111\/all.14240","article-title":"Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma","volume":"75","author":"Jutel","year":"2020","journal-title":"Allergy"},{"key":"R144-20261109","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/all.13598","article-title":"Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma","volume":"74","author":"Wahn","year":"2019","journal-title":"Allergy"},{"key":"R145-20261109","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100487","article-title":"Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study","volume":"13","author":"Florido-Lopez","year":"2020","journal-title":"World Allergy Organ J"},{"key":"R146-20261109","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4168\/aair.2020.12.1.99","article-title":"Efficacy of allergen immunotherapy for allergic asthma in real world practice","volume":"12","author":"Rhyou","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"R147-20261109","article-title":"Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: A nationwide population-based study (EfficAPSI study)","volume":"41","author":"Demoly","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"R148-20261109","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/all.14020","article-title":"The moderating role of allergy immunotherapy in asthma progression: Results of a population-based cohort study","volume":"75","author":"Schmitt","year":"2020","journal-title":"Allergy"},{"key":"R149-20261109","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/all.16052","article-title":"House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study","volume":"79","author":"Jutel","year":"2024","journal-title":"Allergy"},{"key":"R150-20261109","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/all.13213","article-title":"Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis","volume":"73","author":"Zielen","year":"2018","journal-title":"Allergy"},{"key":"R151-20261109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cea.14444","article-title":"Long-term effects of pollen allergoid tyrosine-adsorbed subcutaneous immunotherapy on allergic rhinitis and asthma","volume":"54","author":"Vogelberg","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"R152-20261109","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12382","article-title":"House dust mite immunotherapy: A real-world, prescription data-based analysis","volume":"14","author":"M\u00f6sges","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"R153-20261109","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1111\/all.15454","article-title":"Update on pathomechanisms and treatments in allergic rhinitis","volume":"77","author":"Zhang","year":"2022","journal-title":"Allergy"},{"key":"R154-20261109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1274241","article-title":"Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: A systematic review and meta-analysis","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"R155-20261109","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4168\/aair.2022.14.6.604","article-title":"Chinese guideline on allergen immunotherapy for allergic rhinitis: The 2022 update","volume":"14","author":"Wang","year":"2022","journal-title":"Allergy Asthma Immunol Res"},{"key":"R156-20261109","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/all.13317","article-title":"EAACI guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis","volume":"73","author":"Roberts","year":"2017","journal-title":"Allergy"},{"key":"R157-20261109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1658826","article-title":"Efficacy of different allergen-specific immunotherapies for the treatment of allergic rhinitis in children and adults: An umbrella review","volume":"16","author":"He","year":"2025","journal-title":"Front Immunol"},{"key":"R158-20261109","article-title":"Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis\/rhinoconjunctivitis with or without asthma (MT-12): A randomised, double-blind, placebo-controlled, phase III trial","volume":"48","author":"Schuster","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"R159-20261109","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/all.16363","article-title":"The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial","volume":"80","author":"Gappa","year":"2024","journal-title":"Allergy"},{"key":"R160-20261109","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/all.16387","article-title":"Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy","volume":"80","author":"M\u00f6sges","year":"2024","journal-title":"Allergy"},{"key":"R161-20261109","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1016\/j.jaip.2021.06.060","article-title":"Disease-modifying effect of Japanese cedar pollen sublingual immunotherapy tablets","volume":"9","author":"Yonekura","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R162-20261109","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaci.2023.02.024","article-title":"Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study","volume":"152","author":"Contoli","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R163-20261109","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaci.2019.06.049","article-title":"Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence","volume":"145","author":"Bousquet","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R164-20261109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2217\/imt-2022-0215","article-title":"Real-world study: Drug reduction in children with allergic rhinitis and asthma receiving immunotherapy","volume":"15","author":"S\u00e1nchez","year":"2023","journal-title":"Immunotherapy"},{"key":"R165-20261109","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2022.09.020","article-title":"Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms","volume":"151","author":"Yepes-Nu\u00f1ez","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R166-20261109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/medicina59010015","article-title":"The effectiveness of allergen immunotherapy in adult patients with atopic dermatitis allergic to house dust mites","volume":"59","author":"Bogacz-Piaseczy\u0144ska","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"R167-20261109","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaip.2021.10.060","article-title":"Efficacy of house dust mite sublingual immunotherapy in patients with atopic dermatitis: A randomized, double-Blind, placebo-controlled trial","volume":"10","author":"Langer","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R168-20261109","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5415\/apallergy.0000000000000202","article-title":"What has changed with subcutaneous immunotherapy against house dust mites? Eight-year, single-center real-world data","volume":"15","author":"Bulbul","year":"2025","journal-title":"Asia Pac Allergy"},{"key":"R169-20261109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40413-016-0106-3","article-title":"Debates in allergy medicine: Specific immunotherapy efficiency in children with atopic dermatitis","volume":"9","author":"Slavyanakaya","year":"2016","journal-title":"World Allergy Organ J"},{"key":"R170-20261109","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Chu","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R171-20261109","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101043","article-title":"Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators","volume":"18","author":"Liu","year":"2025","journal-title":"World Allergy Organ J"},{"key":"R172-20261109","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101090","article-title":"Atopic dermatitis occurrence and progression and allergen immunotherapy: A real-world, retrospective cohort study in Germany","volume":"18","author":"Pfaar","year":"2025","journal-title":"World Allergy Organ J"},{"key":"R173-20261109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12016-025-09108-4","article-title":"Recent Advances in oral immunotherapy for food allergies","volume":"68","author":"Sato","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"R174-20261109","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2024.12.1022","article-title":"Treatment of multi-food allergy with omalizumab compared to omalizumab-facilitated multi-allergen OIT","volume":"155","author":"Wood","year":"2025","journal-title":"J Allergy ClinImmunol"},{"key":"R175-20261109","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.anai.2025.02.018","article-title":"Venom allergen immunotherapy in children: Short-term efficacy and impact on quality of life","volume":"135","author":"Kazancioglu","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R176-20261109","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pccm.2023.08.001","article-title":"From gene identifications to therapeutic targets for asthma: Focus on great potentials of TSLP, ORMDL3, and GSDMB","volume":"1","author":"Zhang","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"R177-20261109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaci.2009.11.022","article-title":"Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma","volume":"125","author":"Massanari","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R178-20261109","doi-asserted-by":"crossref","first-page":"901","DOI":"10.5114\/aoms.2015.48546","article-title":"Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: A case series from Poland","volume":"11","author":"Stelmach","year":"2015","journal-title":"Arch Med Sci"},{"key":"R179-20261109","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/alr.23268","article-title":"Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials","volume":"14","author":"Zhang","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"R180-20261109","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.alit.2022.05.010","article-title":"Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis","volume":"71","author":"Hoshino","year":"2022","journal-title":"Allergol Int"},{"key":"R181-20261109","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R182-20261109","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaip.2025.05.003","article-title":"Combination of allergen-specific immunotherapy with biologics in severe asthma: Counterintuitive or rational?","volume":"13","author":"Larenas-Linnemann","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R183-20261109","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2500\/aap.2025.46.250058","article-title":"Pediatric allergen immunotherapy in the United States: Current practice, safety, and unmet needs for long-term and preventive outcomes","volume":"46","author":"Wallace","year":"2025","journal-title":"Allergy Asthma Proc"},{"key":"R184-20261109","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102494","article-title":"Role of allergen immunotherapy and biologics in allergic diseases","volume":"91","author":"Zhou","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"R185-20261109","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2500\/aap.2022.43.220015","article-title":"Standardized allergen extracts for allergen immunotherapy","volume":"43","author":"Nelson","year":"2022","journal-title":"Allergy Asthma Proc"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:02:00Z","timestamp":1794222120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":185,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004189","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"2025-12-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}